Source: https://prcsg.org/index.php/publications/abstracts
Timestamp: 2019-04-20 08:18:22+00:00

Document:
H. I. Brunner, N. Ruperto, D .J. Lovell, G.Horneff, M. Gámir-Gámir, M. Hufnagel,J, Hsu, M. Bao, W. Douglass, N. L. Mallalieu, C. Wells, C. M. Mela, F. De Benedetti.
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Systemic Juvenile Idiopathic Arthritis.
H. I. Brunner, N. Ruperto, A. Martini, A. V. Ramanan, R. J. Cuttica, J. E. Weiss, M. Henrickson, H. Schmeling, J. Anton, K. Minden, G.Horneff, M. Gámir-Gámir, M. Hufnagel, W. Douglass, C. Wells, S. Wimalasundera, N. L. Mallalieu, D .J. Lovell and F. De Benedetti.
Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis.
D. J. Lovell, N. Ruperto, A. Reiff, L. Jung, K. Jarosova, R. Mouy, I. Koné-Paut, O.Y. Jones, V. Vargova, C. Wouters, I. Galindo, C. Mak, H. I. Brunner and A. Martini.
Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years.
H. I. Brunner, N. Ruperto, K. Nanda, M. Toth, I. Foeldvari, J. F. Bohnsack, D. Milojevic, D. J. Kingsbury, K. A. Marzan, E. Chalom, G. Horneff, R. M. Kuester, J. A. Dare, M. Trachana, M. Bereswill, H. Kupper, D. Lovell and A. Martini.
N. Ruperto, H. I. Brunner, G. Vega-Cornejo, A. Berman, R. J. Cuttica, F. Ávila-Zapata, M. Henrickson, D. J. Kingsbury, J. F. Bohnsack, T. Lutz, N. E. Rubio-Perez, V. Gerloni, X. Li, M. Nys, R. Wong, A. Martini and D. J. Lovell.
Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months by Juvenile Idiopathic Arthritis Disease Category.
E. Morgan, A. Consolaro, J. Munro, J. Horonjeff, B. M. Feldman, H. Clairman, C. O. Bingham III, A. Alongi, V. Strand, M. van Rossum, R. Veselý, H. I. Brunner, D Horton, D. J. Lovell, S. Ringold, N. Ruperto, S. Schrandt, N. J. Shiff, K.Toupin-April and B.Shea.
New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis.
N. Ruperto, D. J. Lovell, N. Tzaribachev, A. Zeft, R. Cimaz, V. Stanevica, G. Horneff, J. Bohnsack, T. A. Griffin, R. Carrasco, M. Trachana, J. A. Dare, I. Foeldvari, R. K. Vehe, T. A. Simon, A. Martini and H. I. Brunner.
Longitudinal Effectiveness of Abatacept in Juvenile Idiopathic Arthritis: Results From an Ongoing JIA Registry. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018.
H. Brunner, N. Ruperto, D. Lovell, I. Calvo-Penedes, G. Horneff, M. Gamir Gamir, M. Hufnagel, J. Hsu, M. Bao, W. Douglass, N. Mallalieu, C. Wells, C. Mela and F. De Benedetti.
N. Ruperto, H. I. Brunner, N. Tzaribachev, G. Vega-Cornejo, I. Louw, I. Foeldvari, V. Keltsev, M. E. P. Gastanaga, C. Wouters, R. Joos, B. Lauwerys, K. Minden, J. C. Breedt, X. Li, M. Nys, R. Wong, D. J. Lovell and A. Martini.
Antibody Responses to Diptheria/Tetanus Vaccine in Paediatric Patients with Polyarticular-course Juvenile Idiopathic Arthritis Receiving Subcutaneous Abatacept. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018.
F. Benedetti, N. Ruperto, D. Lovell, G. Horneff, M. Gámir Gámir, M. Hufnagel, J. Hsu, M. Bao, W. Douglass, N. Mallalieu, C. Wells, C. Mela, H. I. Brunner, and PRINTO and PRCSG Investigators.
Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018.
N. Ruperto, H. I. Brunner, K. Nanda, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, D. J. Kingsbury, K. Marzan, E. Chalom, G. Horneff, R. Kuester, J. Dare, M. Trachana-Pilavaki, M. Bereswill, H. Kupper, A. Martini, and D. Lovell.
The Safety Profile of Adalimumab Across Geographic Regions and Dosing Administrations Among Patients With Juvenile Idiopathic Arthritis Enrolled in the STRIVE Registry. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018.
T. Simon, M. Bradley, D. Lovell, B. Shakley, C. Zhang, L. Clark, N. Ruperto, D. McDonald, and H. I. Brunner.
USING ETHNOGRAPHY to Understand Transition in Young Adults with JIA. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018.
N. Ruperto, H. Brunner, N. Tzaribachev, I. Louw, I. Calvo, G. Horneff, M. Henrickson, M. Rama, M. Fischbach, T. Miraval, M. Ally, X. Li, R. Wong, M. Nys, B. Murthy, K. Lin, J. Passarell, A. Martini and D. Lovell.
H. I. Brunner, N. Ruperto, Vega-Cornejo, A. Berman, I. Calvo, R. Cuttica, F. Ãvila-Zapata, M. Henrickson, D. Kingsbury, D. Viola, V. Keltsev, K. Minden, J. F. Bohnsack, X. Li, M. Nys, R. Wong, S. Banerjee, D. J. Lovell and A. Martini.
D. J. Lovell, N. Ruperto, N. Tzaribachev, A. Zeft, R. Cimaz, V. Stanevica, G. Horneff, J. F. Bohnsack, T. A. Griffin, R. Carrasco, M. Trachana, J. A. Dare, I. Foeldvari, R. K. Vehe, T. Simon, H. I. Brunner and A. Martini.
H Brunner, N Ruperto, P Quartier, T Constantin, E Alexeeva, R Schneider, I Kone-Paut, KN Schikler, K Marzan, N Wulffraat, S Padeh, V Chasnyk, C Wouters, JB Kuemmerle-Deschner, T Kallinich, B Lauwerys, E Haddad, EL Nasonov, M Trachana, O Vougiouka, K Leon, A Speziale, K Lheritier, E Vritzali, A Martini and D. Lovell.
N. Ruperto, H. Brunner, K. Nanda, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, C. Rabinovich, D. Kingsbury, K. Marzan, P. Quartier, K. Minden, E. Chalom, G. Horneff, R. Kuester, J. Dare, M. Bereswill, J. Kalabic, H. Kupper, A. Martini and D. Lovell.
N. Ruperto, H. Brunner, N. Tzaribachev, G. Vega-Cornejo, I. Louw, J. Anton, D. Viola, I. Foeldvari, V. Keltsev, D. Kingsbury, C. Wouters, B. Lauwerys, E. Alemao, R. Wong, M. Nys, S. Banerjee, A. Martini and D. Lovell.
H Brunner, N Ruperto, K Nanda, M Toth, I Foeldvari, JF Bohnsack, D Milojevic, CE Rabinovich, D Kingsbury, K Marzan, P Quartier, K Minden, E Chalom, G Horneff, RM Kuester, JA Dare, M Bereswill, J Kalabic, H Kupper, DJ Lovell and A. Martini.
H Brunner, N Ruperto, A Martini, A Ramanan, R Cuttica, JE Weiss, M Henrickson, H Schmeling, J Anton, K Minden, J Hsu, K Bharucha, S Wimalasundera, AK Kadva, R Upmanyu, NL Mallalieu, D Lovell and F. De Benedetti.
E. Baildam, F. De Benedetti, N. Ruperto, H. Brunner, C. Keane, C. Wells, J. Wang, I. Calvo, R. Cuttica, A. Ravelli, R. Schneider, D. Eleftheriou, C. Wouters, R. Xavier, L. Zemel, R. Burgos-Vargas, P. Dolezalova, S. M. Garay, R. Joos, A. Grom, N. Wulffraat, Z. Zuber, F. Zulian, A. Martini and D. Lovell.
N. Ruperto, D. Lovell, C. Wallace, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, E. Rabinovich, D. Kingsbury, K. Marzan, P. Quartier, K. Minden, E. Chalom, G. Horneff, R. Kuester, J. Dare, M. Heinrich, H. Kupper, J. Kalabic, A. Martini and H. Brunner.
HI Brunner, N Ruperto, P Quartier, T Constantin, E Alexeeva, I KonÃ©-Paut, K Marzan, N Wulffraat, R Schneider, S Padeh, V Chasnyk, C Wouters, JB Kuemmerle-Deschner, T Kallinich, B Lauwerys, E Haddad, EL Nasonov, M Trachana, O Vougiouka, K Leon, E Vritzali, K Lheritier, A Martini and DJ. Lovell.
HI Brunner, N Ruperto, V Keltsev, E Alexeeva, C Abud-Mendoza, H Schmeling, MDR Maldonado-VelÃ¡zquez, N Rubio-PÃ©rez, M Stanislav, V Chasnyk, D Brown, M Henrickson, D Kingsbury, CE Rabinovich, A Zeft, E Silverman, M Wang, P Charlton, R Lledo-Garcia, L Shaughnessy, DJ Lovell and A Martini.
D Lovell, N Ruperto, N Tzaribachev, G Vega-Cornejo, I Louw, A Berman, I Calvo, R Cuttica, G Horneff, F Avila-Zapata, J Anton, R Cimaz, E Solau-Gervais, R Joos, G Espada, X Li, M Nys, R Wong, S Banerjee, HI Brunner and A. Martini.
I Foeldvari, N Ruperto, DJ Lovell, G Horneff, HI Huppertz, P Quartier, G Simonini, M Bereswill, J Kalabic, A Martini and HI. Brunner.
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Paediatric Patients from Two To Less than Eighteen Years of Age with Juvenile Idiopathic Arthritis.
Long-Term Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 5-Year Follow-up of An Open-Label Trial.
Treating To Target with Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis: Results from The Long-Term Extension The Phase III Pivotal Trial.
Safety and Effectiveness of Adalimumabmethotrexate for The Treatment of Polyarticular Juvenile Idiopathic Arthritis (PJIA): Strive Registry.
Subcutaneous Abatacept in Patients with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response To Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety.
Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis Patients Previously Exposed to Biologics.
Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study.
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis.
Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program.
Clinical and Functional Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis Following Treatment with Adalimumab.
Efficacy and Safety of Adalimumab in Adult Patients with Polyarticular Juvenille Idiopathic Arthritis.
Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis.
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry.
A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study .
A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH.
A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight. Arthritis & Rheumatology.
A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis.
A Pharmacometric-Based Analysis Indicated No Relationship Between Occurrence of Safety Events and Canakinumab Exposure In Systemic Juvenile Idiopathic Arthritis Patients.
Changes in Gene Expression and Inflammatory Proteins in Systemic Juvenile Idiopathic Arthritis Patients on Canakinumab Therapy.
Maintenance of Efficacy by Canakinumab Treatment in Systemic Juvenile Idiopathic Arthritis Patients.
Long-term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis.
A169: Cumulative Long-Term Safety, Efficacy and Patient-Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment.
A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH.
A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis .
A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study.
Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data.
Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study.
Understanding the biology and use of TNF therapy in jia-clinical outcomes.
Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients.
Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA -- an analysis of 12-week pooled data.
Efficacy of canakinumab in biologic-naive versus previously biologic-exposed SJIA patients: a 12-week pooled post-hoc analysis.
Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients.
Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset.
High levels of DEK autoantibodies may predict early flare following cessation of anti-TNF therapy in juvenile idiopathic arthritis.
Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial.
A12: The Role of Serum S100A12 Protein Levels in Disease Flare After Withdrawal of Anti-tumor Necrosis Factor Therapy in Polyarticular Forms of Juvenile Idiopathic Arthritis.
A20: Understanding the Use and Biology of TNF Therapy in JIA-Clinical Outcomes.
A44: High Levels of DEK Autoantibodies May Predict Early Flare Following Cessation of Anti-TNF Therapy.
Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: Results from the TENDER trial.
A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results.
An Exploratory Analysis of Predictors of Response from 12-Weeks of Canakinumab Therapy in Patients with Active Systemic Juvenile Idiopathic Arthritis..
Canakinumab in Biologic-naive Versus Previously Biologic-Exposed Systemic Juvenile Idiopathic Arthritis Patients: Efficacy Results from a 12 Week Pooled Post Hoc Analysis.
Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA-an analysis of 12-week pooled data.
Efficacy of Biologic Treatments in Juvenile Idiopathic Arthritis with a Polyarticular Course: and Indirect Comparison.
Efficacy and Safety of Tocilizumab in Polyarticular Juvenile Idiopathic Arthritis: Cherish Results at Week 40.
Pharmacokinetics and pharmacodynamics of long-termtocilizumab therapy in polyarticular juvenile idiopathic arthritis.
Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH.
Efficacy and Safety Of Tocilizumab In Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From Cherish.
Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy.
Canakinumab In The Treatment Of Systemic Juvenile IdiopathicArthritis: Results From a 12-Week Pooled Post-Hoc Analysis ForEfficacy.
Marked Improvement In Patient Reported Outcomes Of Children With Active Systemic Juvenile Idiopathic Arthritis With Canakinumab Treatment â€“ Results Of The Phase III Program.
Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients.
Baseline characteristics of patients with active systemic JIA successfully discontinuing corticosteroid while receiving canakinumab: secondary analysis from a pivotal Phase 3 trial.
Canakinumab Improves Health-Related Quality of Life (HRQOL) and Daily Functioning in Systemic Juvinile Idiopathic Arthritis (SJIA) Patients.
Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients .
Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis.
Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy.
Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis.
Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial.
Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA).
Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study .
Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study.
Pharmacokinetics and pharmacodynamics of long-termtocilizumab therapy in patients with systemic juvenile idiopathicarthritis.
Efficacy and Safety of Tocilizumab in Patients with Polyarticular JuvenileIdiopathic Arthritis: Data From a Phase 3 Trial.
Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis.
Efficacy and Safety of Canakinumab in Patients with Active SystemicJuvenile Idiopathic Arthritis and Fever: Results From Two Pivotal Phase 3 Trials.
Analysis of Biomarkers in Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy.
Baseline Characteristics Of Patients With Active Systemic JIA On Canakinumab Therapy Successfully Discontinuing Corticosteroids: Secondary Analyses From A Pivotal PHASE 3 Study.
Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: 2-year data from a phase 3 clinical trial.
MRI Findings from the Trial of Early Aggressive Therapy (TREAT) Study.
Predictors for the Effectiveness of Dexamethasone Iontophoresis for the Treatment of TMJ-Involvement in JIA.
Understanding the Biology and Use of Anti-TNF Agents in JIA - Interim Results.
The Effects of Early Aggressive Therapy in JIA: Results of the TREAT Study.
Efficacy and Safety of Tocilizumab (TCZ) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): TENDER 52-Week Data.
Long-Term Efficacy and Safety of Adalimumab for up to 6 Years in Patients with Juvenile Idiopathic Arthritis.
Tocilizumab Is Efficacious in Patients with Systemic Juvenile Idiopathic Arthritis Across Baseline Demographic and Disease Characteristics and Prior/Baseline Treatments: 52-Week Data From a Phase 3 Clinical Trial.
Phase III Study Results on the Efficacy and Safety of Canakinumab, a Long-Acting, Fully Human Anti-Interleukin-1 Antibody, in Systemic Juvenile Idiopathic Arthritis with Active Systemic Features.
Pharmacokinetics and Pharmacodynamics of Tocilizumab in Systemic Juvenile Idiopathic Arthritis .
Efficacy and Safety of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 2-year Data From a Phase 3 Clinical Trial.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis.
Pharmacokinetics (PK) and Pharmacodynamics (PD) OF Tocilizumab (TCZ) in Systemic Juvenile Idiopathic Arthritis (sJIA).
Efficacy and Safety of Tocilizumab (TCZ) in Patients (pts) with Systemic Juvenile Idiopathic Arthritis (sJIA): TENDER 52-Week Data .
The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial.
Effectiveness of Dexamethasone Iontophoresis in Temporomandibular Joint (TMJ)-Arthritis in Juvenile Idiopathic Arthritis (JIA).
Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: Efficacy Data from the Placebo-Controlled 12-Week Part of the Phase 3 TENDER Trial.
Efficacy and Safety of Tocilizumab In Patients With Systemic Juvenile Idiopathic Arthritis (sJIA): 12-Week Data From The Phase 3 TENDER Trial.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week Data From the Phase 3 TENDER Study.
Efficacy and Safety of Tocilizumab (TCZ) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-Week Data From the Phase 3 TENDER Trial.
Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week Pharmacokinetics (PK) and Pharmacodynamics (PD) Data from the Phase 3 TENDER Trial.
Tocilizumab Improves Systemic and Laboratory Features of Systemic Juvenile Idiopathic Arthritis: 12-Week Data from the Phase 3 TENDER Trial.
Tocilizumab Is Efficacious in Patients With Systemic Juvenile Idiopathic Arthritis Across Baseline Disease Characteristics and Prior or Baseline Treatments: 12-week Data From the Phase 3 TENDER Trial.
Effects of Long-Term Treatment with Etanercept on Growth in Children with Polyarticular Course or Systemic Juvenile Rheumatoid Arthritis.
The Long-term Safety of Etanercept (EnbrelÂ®) in Children with Polyarticular or Systemic Juvenile Rheumatoid Arthritis..
Safety and Efficacy of Over 8 Years of Continuous Etanercept (EnbrelÂ®) Therapy in Patients With Juvenile Rheumatoid Arthritis.
Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis.
Safety over 8 years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis..
Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Data over two years of treatment in a phase III trial..
Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Converting from body surface area dosing to fixed dosing in the open-label extension (OLE) of a phase III study..
Re-establishment of clinical benefit in patients with juvenile idiopathic arthritis after abatacept withdrawal and subsequent re-introduction..
Clinical trial safety data of events of interest in patients receiving etanercept across approved indications..
Two-year efficacy of adalimumab in children with juvenile rheumatoid arthritis (JRA): Results of a phase III trial..
Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis: Results of a double-blind withdrawal phase..
Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long-acting IL-1 inhibitor in systemic juvenile rheumatoid arthritis..
The long-term safety of etanercept in children with polyarticular or systemic juvenile rheumatoid arthritis..
A new multi-center registry to monitor long-term safety of non-steroidal anti-inflammatory drugs (NSAIDs) including celebrex in juvenile idiopathic arthritis (JIA)..
Safety and efficacy of over 8 years of continuous etanercept (Enbrel) therapy in patients with juvenile rheumatoid arthritis..
Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Converting from body surface area dosing to fixed dosing..
Abatacept Treatment of Juvenile Idiopathic Arthritis (JIA): Safety Report.
Efficacy of Abatacept in Different Sub-populations of Juvenile Idiopathic Arthritis (JIA): Results of a Randomized Withdrawal Study.
Adalimumab is Safe and Effective During Long-term Treatment of Patients with Juvenile Rheumatoid Arthritis: Results from a 2-Year Study .
Safety and Efficacy of Over 8 Years of Continuous Etanercept (Enbrel) Therapy in Patients With Juvenile Rheumatoid Arthritis.
Adalimumab for the Treatment of Patients with Juvenile Rheumatoid Arthritis: Safety and Efficacy After Conversion from Body Surface Area-Dosing to Weight-Based Fixed Dosing.
Preliminary Evidence for Sustained Bioactivity of IL-1 Trap (Rilonacept), A Long Acting IL-I Inhibitor, In Systemic Juvenile Idiopathic Arthritis (SJIA).
Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA): Results of a double-blind withdrawal phase..
A phase IV registry of etanercept in children with juvenile rheumatoid arthritis..
Modulation of inflammatory disease markers after the initiation of infliximab plus methotrexate therapy in patients with juvenile rheumatoid arthritis..
Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long-acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis..
48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA)..
Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA)..
Preliminary evidence for bioactivity of IL-1 Trap (Rilonacept), a long-acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA)..
Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA): Results of the double-blind withdrawal phase..
Assessment of open-label co-stimulation blockade with abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA)..
Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results..
Comparison of safety, efficacy and pharmacokinetics for 3 and 6 mg/kg infliximab plus methotrexate therapy in JRA patients..
Randomized trial of infliximab (IFX) plus methotrexate (MTX) for the treatment of polyarticular juvenile rheumatoid arthritis (JRA)..
The effect of infliximab on the modulation of inflammatory disease markers in patients with juvenile rheumatoid arthritis..
Etanercept therapy in children with juvenile rheumatoid arthritis: Four year outcome..
Study outcomes for etanercept therapy in children with and adolescents with juvenile rheumatoid arthritis (JRA): Update from the pediatric registry..
Safety outcomes from a phase IV pediatric registry: Etanercept (Enbrel) therapy in children and adolescents with juvenile rheumatoid arthritis (JRA)..
Long-term safety and efficacy experience with etanercept (Enbrel) in children with polyarticular juvenile rheumatoid arthritis..
Preliminary data from the study of adalimumab in children with juvenile idiopathic arthritis (JIA)..
Neoral registry in polyarticular juvenile rheumatoid arthritis.
Etanercept/methotrexate registry in juvenile rheumatoid arthritis (JRA).
Preliminary defintions of improvement for juvenile myositis.
International consensus for core sets of outcome measures for disease activity (DA) and disease damage (DD) assessment. Part I: Juvenile Systemic Lupus Erythematosus (JSLE)..
International consensus for the core sets of outcome measures for disease activity (DA) and disease damage (DD) assessment. Part II: Juvenile Dermatomyositis (JDM).
Sustained safety and efficacy of Enbrel (etanercept) in the extended treatment of polyarticular course juvenile rheumatoid arthritis.
Safety and efficacy of Enbrel (etanercept) in the extended treatment of polyarticular course juvenile rheumatoid arthritis.
Tumor necrosis factor (P75) receptor Fc fusion protein, TNFR:FC, (Enbrel) in children with polyarticular course juvenile rheumatoid arthritis.
Safety and Efficacy of tumor necrosis factor receptor P75 Fc fusion protein (TNF:FC, Enbrel) in polyarticular course juvenile rheumatoid arthritis.
Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis II: Early predictors of outcome.
Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis I: Outcome status.
Validation and rater reliability of the childhood myositis assessment scale (C-MAS).
Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: A double-blind, placebo-controlled pilot study.
Intravenous immune globulin in polyarticular JRA: Results of a phase I/II trial.
Preliminary core set of outcome variables for use in JRA clinical trials.
Redundancy of conventional outcome variables used in JRA clinical trials.
Low-dose methotrexate in children with JRA: Results of a post-trial, long-term follow-up program.
Intravenous immune globulin in systemic JRA.
Results of the auranofin long-term follow-up program (AU 109X) in children with juvenile rheumatoid arthritis.
Low-dose methotrexate treatment of recalcitrant JRA: Results of the USA-USSR randomized, controlled trial.
Meta-analysis of anti-rheumatic drug trials in juvenile rheumatoid arthritis.
Ibuprofen suspension in the treatment of JRA: Results of a double-blind, aspirin-controlled trial.
Methotrexate in the treatment of recalcitrant JRA: Results of a double-blind, placebo-controlled, randomized trial.
Auranofin in the treatment of juvenile rheumatoid arthritis: Results of the USA-USSR, double-blind, placebo-controlled trial.
HLA B27-associated arthritis in childhood: Long-term clinical and diagnostic outcomes.
Oral gold (auranofin) in juvenile rheumatoid arthritis (JRA): Results of a double-blind placebo-controlled trial.
Changes in the erythrocyte sedimentation rate correlate poorly with articular disease activity in JRA.
Joint hypermobility in juvenile episodic arthritis/arthralgia (JEA).
D-penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: Results of a double-blind, placebo-controlled trial.
Long-term usage of oral gold (auranofin) in the treatment of children with juvenile rheumatoid arthritis (JRA).
Characteristics of responders (R) and non-responders (NR) to slower-acting anti-rheumatic drugs (SAARDs) in juvenile rheumatoid arthritis (JRA).
Auranofin in the long-term treatment of children with juvenile rheumatoid arthritis.
Generalizations from multiple studies of non-steroidal anti-inflammatory drugs(NSAIDs) in children with juvenile rheumatoid arthritis (JRA).
Serial determinations of circulating immune complexes (CIC) in the sera of children with rheumatic disease.
Early clinical indicators of eventual response to non-steroidal anti-inflammatory drugs (NSAIDs) in patients with juvenile rheumatoid arthritis (JRA).
Auranofin in juvenile rheumatoid arthritis.
Immune complexes in the sera of patients with rheumatic disease.
Cooperative multicentered clinical trial with the USSR: Advantages and difficulties..
Blood gold concentrations in children with juvenile rheumatoid arthritis.
Time course response to non-steroidal anti-inflammatory drugs in patients with juvenile rheumatoid arthritis.
Immune complexes in the sera of pediatric patients with rheumatic disease.
Children at risk of developing ankylosing spondylitis.
Psychosocial functioning in children with juvenile rheumatoid arthritis (JRA) .
Proquazone in the treatment of juvenile rheumatoid arthritis: A segment I study.
Pirprofen in the treatment of juvenile rheumatoid arthritis: A segment I study.
Anti-eye antibody in juvenile rheumatoid arthritis.
A comparative study of the epidemiologic and clinical natural histories of juvenile rheumatoid arthritis.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.